Pulmonary Hypertension

Acceleron Reignites Pipeline After Latest Trial Success With PAH Drug - Seeking Alpha Acceleron Reignites Pipeline After Latest Trial Success With PAH Drug - Seeking Alpha Posted: 31 Jan 2020 05:10 AM PST [unable to retrieve full-text content] Acceleron Reignites Pipeline After Latest Trial Success With PAH Drug    Seeking Alpha In the business of saving lives, cooperation beats competition - Philadelphia - Philadelphia Business Journal Posted: 31 Jan 2020 09:00 PM PST [unable to retrieve full-text content] In the business of saving lives, cooperation beats competition - Philadelphia    Philadelphia Business Journal You are subscribed to email updates from "pulmonary hypertension medications" - Google News . To stop receiving these emails, you may unsubscribe now . Email delivery powered by Google Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United Sta...

Acceleron's pulmonary hypertension treatment meets main goal, shares soar 79% - Reuters Acceleron's pulmonary hypertension treatment meets main goal, shares soar 79% - Reuters Posted: 27 Jan 2020 01:36 PM PST (Reuters) - Acceleron Pharma Inc ( XLRN.O ) said on Monday its investigational treatment for a rare, deadly lung disease called pulmonary arterial hypertension met the main goal in a mid-stage trial, sending its shares surging 79%. The treatment, sotatercept, showed significant reduction in pulmonary vascular resistance versus placebo at week 24. It also showed significant improvements in patients functional capacity, which was determined by a six minute walk test. Pulmonary arterial hypertension, or PAH, occurs when arteries in the lungs constrict, forcing the heart to work harder, often leading to heart failure. Its symptoms include shortness of breath and fatigue. The disease has no cure, but there are treatme...

Acceleron’s pulmonary hypertension treatment meets main goal, shares soar 79% - Physician&#039;s Weekly Acceleron’s pulmonary hypertension treatment meets main goal, shares soar 79% - Physician&#039;s Weekly Posted: 27 Jan 2020 02:19 PM PST (Reuters) – Acceleron Pharma Inc <XLRN.O> said on Monday its investigational treatment for a rare, deadly lung disease called pulmonary arterial hypertension met the main goal in a mid-stage trial, sending its shares surging 79%. The treatment, sotatercept, showed significant reduction in pulmonary vascular resistance versus placebo at week 24. It also showed significant improvements in patients functional capacity, which was determined by a six minute walk test. Pulmonary arterial hypertension, or PAH, occurs when arteries in the lungs constrict, forcing the heart to work harder, often leading to heart failure. Its symptoms include shortness of breath and fatigue. The disea...

Knowledge Is Power When Dealing with Sarcoidosis - Sarcoidosis News Knowledge Is Power When Dealing with Sarcoidosis - Sarcoidosis News Posted: 31 Jan 2020 07:00 AM PST The first month of the year has been an eventful one for me, to say the least. I spent much of January taking tests to evaluate my current health status and visiting the various doctors on my team. It has been a busy month for my wife, too, as she accompanied me to many appointments. Last week, I met with my pulmonologist to discuss the results of my tests and potential therapies. Sarcoidosis doesn't take a break after you've been diagnosed. During the first week of 2020, I had 62 blood tests, eight lung imaging tests, an electrocardiogram , an echocardiogram, a cardiac stress test, and pulmonary function tests . Needless to say, my medical team now knows everything about me, including what I want to be when I grow up!  Before I attended my follow-up appointm...

Acceleron’s pulmonary hypertension treatment meets main goal, shares soar 79% - Physician&#039;s Weekly Acceleron’s pulmonary hypertension treatment meets main goal, shares soar 79% - Physician&#039;s Weekly Posted: 27 Jan 2020 02:19 PM PST (Reuters) – Acceleron Pharma Inc <XLRN.O> said on Monday its investigational treatment for a rare, deadly lung disease called pulmonary arterial hypertension met the main goal in a mid-stage trial, sending its shares surging 79%. The treatment, sotatercept, showed significant reduction in pulmonary vascular resistance versus placebo at week 24. It also showed significant improvements in patients functional capacity, which was determined by a six minute walk test. Pulmonary arterial hypertension, or PAH, occurs when arteries in the lungs constrict, forcing the heart to work harder, often leading to heart failure. Its symptoms include shortness of breath and fatigue. The disea...

Life Hacks that Help Me to Live with PH - Pulmonary Hypertension News Life Hacks that Help Me to Live with PH - Pulmonary Hypertension News SNUH team finds method to detect pulmonary arterial hypertension early - Korea Biomedical Review Remembering that It&#039;s OK to Not Be OK: PH and Mental Health - Pulmonary Hypertension News For Blake: Global kindness movement honors East Lansing native&#039;s young son - Lansing State Journal Urinary NT-proBNP Has Potential as Biomarker for PH in Premature... - Pulmonary Hypertension News Life Hacks that Help Me to Live with PH - Pulmonary Hypertension News Posted: 31 Jan 2020 07:00 AM PST We don't always have a choice about what life throws our way. But our response to challenges is something we can control. Living with pulmonary hypertension (PH), I don't always have control over my body. With that lack of control comes frustr...